Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353272 | 0.84 | ALDH1A1 (0.50) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL4293546 | 0.84 | ERN1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL584614 | 0.84 | ERN1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL5643995 | 0.80 | ERN1 (0.59) | ERN1 | |
| SCHEMBL21121085 | 0.80 | TDP1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL23065826 | 0.80 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL9712525 | 0.80 | TDP1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL16415856 | 0.80 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL10290090 | 0.80 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL19948618 | 0.80 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-115583899-B | Preparation method of quantum dot catalytic amino butyronitrile compound | 浙江理工大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-115583899-A | Preparation method of quantum dot catalyzed aminobutyronitrile compound | 浙江理工大学 | 2023-01-10 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-1313691-A2 | FLUORINATED AND CHLORINATED BENZALDEHYDES | Milliken & Company (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1313690-A1 | METHOD OF PRODUCING FLUORINATED AND CHLORINATED BENZALDEHYDES AND COMPOSITIONS THEREOF | Milliken & Company (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6548581-B2 | Radiation transparent polyolefin | MILLIKEN & COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030013786-A1 | Novel asymmetric halogen-alkyl alditol derivatives as nucleators and clarifiers for polyolefins, and polyolefin plastic compositions containing same | MILLIKEN & COMPANY | 2003-01-16 | — | — | US | disclosed |
| US-20020062034-A1 | Novel fluorinated and alkylated alditol derivatives and compositions and polyolefin articles containing same | MILLIKEN &COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2002020452-A2 | NOVEL FLUORINATED AND CHLORINATED BENZALDEHYDES | MILLIKEN & COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020447-A1 | METHOD OF PRODUCING FLUORINATED AND CHLORINATED BENZALDEHYDES AND COMPOSITIONS THEREOF | MILLIKEN & COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020528-A2 | FLUORINATED AND ALKYLATED ALDITOL DERIVATIVES AND POLYOLEFIN ARTICLES CONTAINING SAME | MILLIKEN & COMPANY (US) | 2002-03-14 | — | — | WO | disclosed |
| US-6300525-B1 | CONTACTING SUBSTITUTED BENZENE IN CARBON MONOXIDE ATMOSPHERE HAVING SPECIFIED PRESSURE IN PRESENCE OF METAL HALIDE AND HYDROHALIC ACID CATALYST AND AT SPECIFIED TEMPERATURE | MILLIKEN & COMPANY | 2001-10-09 | — | — | US | disclosed |
| US-6297405-B1 | EFFICIENTLY PRODUCED BENZALDEHYDE CHEMICAL INTERMEDIATE SUBSTITUTED BY ONE HALOGEN AND ALKYL OR CYCLOALKYL GROUPS AT OTHER POSITIONS | MILLIKEN & COMPANY | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ERN1 225/4885ALDH1A1 1103/4885TSHR 840/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | ERN1 225/4885ALDH1A1 1103/4885TSHR 840/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | ERN1 225/4885ALDH1A1 1103/4885TSHR 840/4885 |
| US-20020062034-A1 | Novel fluorinated and alkylated alditol derivatives and compositions and polyolefin articles containing same | ALDOA, SORD, DERA | ERN1 2583/4885ALDH1A1 110/4885TSHR 4548/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | ERN1 400/4885ALDH1A1 1397/4885TSHR 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.